MIVOLIS Sweetener Tablets 2400 pcs. - Table Sweeteners | Germany

Product Information

Renal effects. NSAIDs inhibit the synthesis of renal prostaglandins, which play a supportive role in the maintenance of renal perfusion. In patients whose renal blood flow and blood volume are decreased, administration of an NSAID may precipitate overt renal decompensation which is typically followed by recovery to pretreatment state upon discontinuation of nonsteroidal anti-inflammatory therapy. Conditii de pastrare: se va pastra intr-un loc uscat, la o temperatura de pana la 25C. Nu se va lasa la indemana copiilor.

Combination use of ACE inhibitors or angiotensin receptor antagonists, anti-inflammatory drugs and thiazide diuretics. The use of an ACE inhibiting drug (ACE inhibitor or angiotensin receptor antagonist), an anti-inflammatory drug (NSAID or COX-2 inhibitor) and a thiazide diuretic at the same time increases the risk of renal impairment. This includes use in fixed combination products containing more than one class of drug. Combined use of these medications should be accompanied by increased monitoring of serum creatinine, particularly at the institution of the combination. The combination of drugs from these three classes should be used with caution particularly in elderly patients or those with pre-existing renal impairment. Contracepţie: Scăderea eficacităţii dispozitivelor intrauterine de către AINS a fost raportată anterior, dar este necesară o confirmare ulterioară. Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with Movalis orodispersible tablets after careful consideration. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).

Interaction

In dialysis patients with severe renal failure, the dose should not exceed 7.5 mg (half a 15 mg tablet) per day. The efficacy of meloxicam in treating the symptoms of osteoarthritis has been confirmed in several clinical studies. Two clinical studies of six months duration were performed in patients with osteoarthritis of the hip or knee. In the first study, the efficacy of meloxicam 15 mg (n = 306) and piroxicam 20 mg (n = 149) were found to be comparable, using as efficacy endpoints improvement in overall pain, pain on movement, global efficacy, change in duration of inactivity and change in quality of life score. In the second study, the efficacy of meloxicam 7.5 mg (n = 169) was found to be comparable to that of diclofenac 100 mg SR (n = 167) using similar endpoints. Antihipertensive (de exemplu, beta-blocante, inhibitori de angiotensin-convertază, vasodilatatoare, diuretice): Pe perioada tratamentului cu AINS s-a raportat o scădere a efectului medicamentelor antihipertensive prin inhibarea prostaglandinelor vasodilatatoare. The Movalis phase II/III safety database includes 10,122 patients treated with Movalis 7.5 mg/day and 3505 patients treated with Movalis 15 mg/day. Movalis at these doses was administered to 661 patients for at least six months and to 312 patients for at least one year. Approximately 10,500 of these patients were treated in ten placebo and or active controlled osteoarthritis trials. GI adverse events were the most frequently reported adverse events in all treatment groups across Movalis trials.

Not all of these side effects have been reported with MOVALIS but have been seen with similar medicines. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms. The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis. NSAIDs, by inhibiting the vasodilating effect of renal prostaglandins, may induce a functional renal failure by reduction of glomerular filtration. This adverse event is dose-dependant. At the beginning of the treatment, or after dose increase, careful monitoring of diuresis and renal function Driving and operating machinery. There are no specific studies about effects on the ability to drive vehicles and to use machinery. Patients who experience visual disturbances, drowsiness or other central nervous system disturbances should refrain from these activities.Carcinogenicity. Two year dietary studies showed no evidence for carcinogenic activity at meloxicam doses up to 0.8 mg/kg/day (approximately half of the highest human dose at 15 mg/day for a 50 kg person based on body surface area [BSA]) in rats and up to 8 mg/kg/day (2.2 times the highest human dose based on BSA) in mice. In rats, the highest dose used was nephrotoxic, while the highest dose used in mice was subtoxic. Hypersensitivity to Movalis or to one of the excipients or hypersensitivity to substances with a similar action, e.g. NSAIDs, aspirin. Movalis should not be given to patients who have developed signs of asthma, nasal polyps, angioneurotic oedema or urticaria following the administration of aspirin or other NSAIDs;